A robustness-based approach to systems-oriented drug design
The DOI matches its Crossref record; 104 of the 105 references it cites were found in a registry or an index.
Abstract
Many potential drugs that specifically target a particular protein considered to underlie a given disease have been found to be less effective than hoped, or to cause significant side effects. The intrinsic robustness of living systems against various perturbations is a key factor that prevents such compounds from being successful. By studying complex network systems and reformulating control and communication theories that are well established in engineering, a theoretical foundation for a systems-oriented approach to more effectively control the robustness of living systems, particularly at the cellular level, could be developed. Here, I use examples that are based on existing drugs to illustrate the concept of robustness, and then discuss how a greater consideration of the importance of robustness could influence the design of new drugs that will be intended to control complex systems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it is commonly the case in complex biochemical networks that while changes in individual parameters have little effect on the behaviour of biochemical pathways—indeed evolution is thought to have selected for robustness to individual parameter changes”
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
The Byzantine generals problem
Lamport, L., Shostak, R., & Pease, M. (1982) · ACM Transactions on Programming Languages and Systems · doi:10.1145/357172.357176 · Cited by 6,023 · cited 1×
“Fail-on failure (also known as Byzantine failure) has been a major problem for communication networks, and is considered to be a crucial problem in complex network systems in genera”
BackgroundDruker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“A further illustrative case is that of imatinib (Gleevec; Novartis), which is considered as a successful example of a drug that targets the protein product of a disease-causative gen”
BackgroundROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Khan, J., Wei, J. S., Ringnér, M., Saal, L. H., Ladanyi, M., Westermann, F., Berthold, F., Schwab, M., Antonescu, C. R., Peterson, C., et al. (2001) · Nature Medicine · doi:10.1038/89044 · Cited by 2,644
Cited by
Items 101–200 of 535
Structural Bioinformatics of the Interactome
Petrey, D., & Honig, B. (2014) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-051013-022726 · Cited by 59
“A systems-level understanding of issues such as these is necessary for a proper understanding of drug efficacy and toxicity (67, 98, 141, 199).”
BackgroundLuo, Y., Wang, Q., & Zhang, Y. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.12.011 · Cited by 65
“With the increasing understanding of complex diseases, the strategy of drug discovery has shifted from the well-accepted “one target, one drug” model to a new “multi-target, multi-drug” model for systemically modulating multiple targets in the human body (Kitano, 2007).”
BackgroundINTERNATIONAL ASSESSMENT OF RESEARCH AND DEVELOPMENT IN SIMULATION-BASED ENGINEERING AND SCIENCE
Glotzer, S. C. (2011) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781848166981 · Cited by 65
Robustness and Information Transfer within IL-6-induced JAK/STAT Signalling
Billing, U., Jetka, T., Nortmann, L., Wundrack, N., Komorowski, M., Waldherr, S., Schaper, F., & Dittrich, A. (2019) · Communications Biology · doi:10.1038/s42003-018-0259-4 · Cited by 64
Controllability in Cancer Metabolic Networks According to Drug Targets as Driver Nodes
Asgari, Y., Salehzadeh‐Yazdi, A., Schreiber, F., & Masoudi‐Nejad, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079397 · Cited by 64
The developmental genetics of biological robustness
Mestek, L., & Barkoulas, M. (2015) · Annals of Botany · doi:10.1093/aob/mcv128 · Cited by 64
“While some developmental systems are affected by such challenges and display variation in phenotypic traits, others continue consistently to produce invariable phenotypes despite perturbation.”
‘Glocal’ Robustness Analysis and Model Discrimination for Circadian Oscillators
Hafner, M., Koeppl, H., Hasler, M., & Wagner, A. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000534 · Cited by 63
“Finally, being posttranslational, the clock shares many features with signal transduction pathways, an important field of application for robustness analysis [43,44].”
BackgroundParadigm shift in natural product research: traditional medicine inspired approaches
Mukherjee, P. K., Bahadur, S., Harwansh, R. K., Biswas, S., & Banerjee, S. (2017) · Phytochemistry Reviews · doi:10.1007/s11101-016-9489-6 · Cited by 63
“Therefore, risk is minimized to pace up the drug development pipeline (Kitano 2007).”
BackgroundNetworked buffering: a basic mechanism for distributed robustness in complex adaptive systems
Whitacre, J. M., & Bender, A. (2010) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-7-20 · Cited by 64
“Discussion There is a long-standing interest in the origins of robustness and resilience within CAS in general and biological systems in particular [28,45,46,48-59].”
BackgroundHajjo, R., Sabbah, D. A., Abusara, O. H., & Bawab, A. Q. A. (2022) · Diagnostics · doi:10.3390/diagnostics12122975 · Cited by 63
Palacios, R., Goñi, J., Martínez‐Forero, I., Iranzo, J., Sepulcre, J., Melero, I., & Villoslada, P. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001222 · Cited by 62
“Moreover, the identification of such pathological interactions might facilitate the development of new therapeutic targets [12, 13].”
BackgroundDrug-therapy networks and the prediction of novel drug targets
Spiro, Z., Kovacs, I. A., & Csermely, P. (2008) · Journal of Biology · doi:10.1186/jbiol81 · Cited by 56
“decrease the effect of buffering weak links to the extent that the disease-affected cell or parasite suffers an ‘error-catastrophe’, where robustness collapses [17,32,34].”
BackgroundInfluentialRoggers, R. A., Lin, V. S. ‐., & Trewyn, B. G. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200613y · Cited by 61
Antal, M., Bode, C., & Csermely, P. (2009) · Current Protein & Peptide Science · doi:10.2174/138920309787847617 · Cited by 62
“This is especially true, if we want to avoid network remodeling-based resistance [76] and want to design drugs, which affect the targets of the grossly altered networks of ‘sick cells’.”
BackgroundDeveloping multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem
Xie, L., & Bourne, P. E. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00209 · Cited by 60
“For example, one of intrinsic properties of biological network is “robust-yet-fragile” (Kitano, 2007).”
BackgroundTarget deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery
Jung, H. J., & Kwon, H. J. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0618-3 · Cited by 60
“In addition, the adverse side effects of a drug may be caused by unwanted cross-reactivity with other biologically relevant targets (Weber et al. 2004; Kitano 2007).”
BackgroundHuman metabolic network reconstruction and its impact on drug discovery and development
Ma, H., & Goryanin, I. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.02.002 · Cited by 59
Medicina P4: el futuro a la vuelta de la esquina
Sobradillo, P., Pozo, F., & Agustí, A. G. N. (2010) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2010.09.009 · Cited by 60
New Approaches to Treating Alzheimer's Disease
Zheng, H., Fridkin, M., & Youdim, M. B. H. (2015) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s13210 · Cited by 59
de Mendizábal, N. V., Carneiro, J., Solé, R. V., Goñi, J., Bragard, J. R., Martínez‐Forero, I., Martinez‐Pasamar, S., Sepulcre, J., Torrealdea, J., Bagnato, F. R., et al. (2011) · BMC Systems Biology · doi:10.1186/1752-0509-5-114 · Cited by 59
“In order to efficiently modulate the dynamics of the immune system it is necessary to know in which region of parameter space the immune system of a given patient is acting at any time, as well as to identify which control mechanism can be targeted [44,46].”
BackgroundNanotechnology in Drug Discovery and Development
Gutiérrez, L., Stepien, G., Gutiérrez, L., Pérez-Hernández, M., Pardo, J., Pardo, J., Grazú, V., & de la Fuente, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12292-9 · Cited by 57
Simultaneous Targeting of COX-2 and AKT Using Selenocoxib-1-GSH to Inhibit Melanoma
Gowda, R., Madhunapantula, S. V., Desai, D. H., Amin, S., & Robertson, G. P. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0492 · Cited by 56
“melanoma cells, these efforts have failed due to development of resistant disease (36).”
Anticipating drug side effects by comparative pharmacology
García-Serna, R., & Mestres, J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.509343 · Cited by 54
“Biological systems are intrinsically robust [50].”
Park, H., Lee, J., Lim, J., & Kang, B. H. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-148 · Cited by 53
“Multicomponent and system-oriented therapeutics development approaches could provide a solution [60,61].”
Structural Systems Pharmacology: The Role of 3D Structures in Next-Generation Drug Development
Duran‐Frigola, M., Mosca, R., & Aloy, P. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.03.004 · Cited by 51
Systems genetics for drug target discovery
Penrod, N. M., Sallari, R. C., & Moore, J. H. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.07.002 · Cited by 51
“However, the system is vulnerable when challenged with perturbations for which these mechanisms cannot cope [63].”
BackgroundSun, Y., Zhu, R., Ye, H., Tang, K., Zhao, J., Chen, Y., Liu, Q., & Cao, Z. (2012) · Briefings in Bioinformatics · doi:10.1093/bib/bbs025 · Cited by 51
“network essence of these diseases [1].”
BackgroundA biological relativity view of the relationships between genomes and phenotypes
Noble, D. (2012) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2012.09.004 · Cited by 50
Fragilities Caused by Dosage Imbalance in Regulation of the Budding Yeast Cell Cycle
Kaizu, K., Moriya, H., & Kitano, H. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000919 · Cited by 47
“Knowing the mechanisms causing cellular fragility is important for controlling cellular functions or finding novel drug targets [27,28].”
BackgroundSelf-citationTse, A., & Verkhivker, G. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166583 · Cited by 50
He, C., Wu, Y., Lai, Y., Cai, Z., Liu, Y., & Lai, L. (2012) · Molecular BioSystems · doi:10.1039/c2mb05503a · Cited by 50
Mathematical Modelling of the MAP Kinase Pathway Using Proteomic Datasets
Tian, T., & Song, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042230 · Cited by 49
“First introduced by Csete and Doyle [32], this theory has been extensively studied by Kitano and co-workers [33,34,35,36].”
BackgroundGogoi, B., Gogoi, D., Silla, Y., Kakoti, B. B., & Bhau, B. S. (2016) · Molecular BioSystems · doi:10.1039/c6mb00807k · Cited by 49
Liu, C., Li, H., Wang, K., Zhuang, J., Chu, F., Gao, C., Liu, L., Feng, F., Zhou, C., Zhang, W., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00368 · Cited by 49
“The evolving method of network pharmacology provides such a paradigm, which aims at identifying compounds that regulate the activity of multiple targets in the impaired mechanisms network and deregulate interactions underlying a disease phenotype, either by targeting multiple pathways or by reducing potential adverse…”
MethodSatyanarayanajois, S. D., & Hill, R. A. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.135 · Cited by 49
Brain Tumor Stem Cells as Therapeutic Targets in Models of Glioma
Laks, D. R., Visnyei, K., & Kornblum, H. I. (2010) · Yonsei Medical Journal · doi:10.3349/ymj.2010.51.5.633 · Cited by 49
Masoudi‐Nejad, A., & Asgari, Y. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.01.007 · Cited by 48
“The structural features of metabolic networks contribute to the robustness and flexibility of the complex biosystems and may explain, in general, the fact that many drug candidates are ineffective (the drug effect is compensated by other pathways in the network) or show unexpected severe side effects [97–99].”
BackgroundLi, J., Du, Q., Li, N., Du, S., & Sun, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111167 · Cited by 47
Quantitative Phosphoproteomics of CXCL12 (SDF-1) Signaling
Wojcechowskyj, J. A., Lee, J. Y., Seeholzer, S. H., & Doms, R. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024918 · Cited by 47
“With this paradigm shift, new tools and perspectives are needed to better understand signaling networks [33,34].”
BackgroundLiu, C., Wang, K., Zhuang, J., Gao, C., Li, H., Liu, L., Feng, F., Zhou, C., Yao, K., Deng, L., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01171 · Cited by 46
“IP aims to find active substances that can intervene in underlying impaired mechanisms and deregulated interactions by modulating the activity of several hubs or by targeting multiple pathways in complex disease networks (Kitano, 2007).”
Tian, S., Li, Y., Li, D., Xu, X., Wang, J., Zhang, Q., & Hou, T. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400146u · Cited by 46
Ho, I.-L., Kuo, K.-L., Liu, S., Chang, H., Hsieh, J., Wu, J., Chiang, C., Lin, W., Tsai, Y., Chou, C.-T., et al. (2015) · Scientific Reports · doi:10.1038/srep16948 · Cited by 46
Satoh, J., Yamamoto, Y., Kitano, S., Takitani, M., Asahina, N., & Kino, Y. (2014) · Journal of Central Nervous System Disease · doi:10.4137/jcnsd.s18103 · Cited by 45
Improving the Robustness of Complex Networks with Preserving Community Structure
Yang, Y., Li, Z., Chen, Y., Zhang, X., & Wang, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116551 · Cited by 45
“Research have however shown that many of these networks are ‘robust yet fragile’ [6–13].”
BackgroundMolecular network analysis of human microRNA targetome: from cancers to Alzheimer’s disease
Satoh, J. (2012) · BioData Mining · doi:10.1186/1756-0381-5-17 · Cited by 47
“The logically arranged molecular networks construct the whole system characterized by robustness, which maintains the proper function of the system in the face of genetic and environmental perturbations [13].”
BackgroundNext generation of network medicine: interdisciplinary signaling approaches
Korcsmáros, T., Schneider, M. V., & Superti‐Furga, G. (2017) · Integrative Biology · doi:10.1039/c6ib00215c · Cited by 46
Molecular networks and system-level properties
Alberghina, L., Höfer, T., & Vanoni, M. (2009) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2009.07.009 · Cited by 45
De, K., Li, X., Tang, G.-Y., & Zhang, H. (2007) · ChemMedChem · doi:10.1002/cmdc.200700291 · Cited by 45
Traditional knowledge of Western herbal medicine and complex systems science
Niemeyer, K., Bell, I. R., & Koithan, M. S. (2013) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2013.03.001 · Cited by 43
Validation and invalidation of systems biology models using robustness analysis
Bates, D. G., & Cosentino, C. (2011) · IET Systems Biology · doi:10.1049/iet-syb.2010.0072 · Cited by 43
Ecoimmunology: is there any room for the neuroendocrine system?
Ottaviani, E., Malagoli, D., Capri, M., & Franceschi, C. (2008) · BioEssays · doi:10.1002/bies.20801 · Cited by 41
Application of Metabolic Flux Analysis in Metabolic Engineering
Lee, S. Y., Park, J. M., & Kim, T. Y. (2011) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-385120-8.00004-8 · Cited by 41
Assessment and modelling of antibacterial combination regimens
Rao, G. G., Li, J., Garonzik, S. M., Nation, R. L., & Forrest, A. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.12.004 · Cited by 41
Khoo, B. L., Grenci, G., Lim, J. S. Y., Lim, Y. P., Fong, J., Yeap, W. H., Lim, S. B., Chua, S. L., Wong, S. C., Yap, Y. S., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0301-9 · Cited by 40
Tse, A., & Verkhivker, G. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130203 · Cited by 39
“bridge microscopic analysis of protein structure networks with macroscopic modeling of cellular networks and signaling pathways [137].”
InfluentialSystems biology of infectious diseases: a focus on fungal infections
Santamaría, R., Rizzetto, L., Bromley, M., Zelante, T., Lee, W., Cavalieri, D., Romani, L. R., Miller, B., Gut, I. G., Santos, M. A. S., et al. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.08.004 · Cited by 39
Clairambault, J. (2009) · Mathematical Modelling of Natural Phenomena · doi:10.1051/mmnp/20094302 · Cited by 39
“Kitano in a series of articles [143, 144, 145], where he proposes that such a robust network must have a “bowtie architecture”, with a limited number of hubs as in an airplane company network.”
BackgroundCause-effect relationships in medicine: a protein network perspective
Fliri, A. F. J., Loging, W., & Volkmann, R. A. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.07.005 · Cited by 39
Human Disease and Drug Pharmacology, Complex as Real Life
Viayna, E., Sola, I., Pietro, O. D., & Muñoz‐Torrero, D. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130002 · Cited by 39
“As diseases are complex, they require complex therapeutic approaches that should target not single proteins but imbalances of multiple proteins within an interaction network [5,17,19,20,29,30,34,38,39].”
BackgroundCryptotanshinone Induces Cell Death in Lung Cancer by Targeting Aberrant Feedback Loops
Vundavilli, H., Datta, A. A., Sima, C., Hua, J., Lopes, R., & Bittner, M. L. (2019) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2019.2958042 · Cited by 38
“therapeutic drugs [4].”
So, J., Pasculescu, A., Dai, A. Y., Williton, K., James, A., Nguyen, V., Creixell, P., Schoof, E. M., Sinclair, J., Barrios‐Rodiles, M., et al. (2015) · Science Signaling · doi:10.1126/scisignal.2005700 · Cited by 39
“Thus, network fragility can be leveraged therapeutically by inhibiting a specific combination of targets, a concept pertinent to the emerging field of network medicine (19, 20).”
BackgroundDIGRE: Drug‐Induced Genomic Residual Effect Model for Successful Prediction of Multidrug Effects
Yang, J., Tang, J. P., Li, Y., Zhong, R., Wang, T.-M., Wong, S. T. C., Xiao, G., & Xie, Y. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.1 · Cited by 38
The History and Implications of Testing Thalidomide on Animals
Greek, R., Shanks, N., & Rice, M. J. (2011) · The Journal of Philosophy Science & Law · doi:10.5840/jpsl20111133 · Cited by 38
“The field of systems biology reflects this change in thinking.[8-10, 17] Attempting to extrapolate between complex systems is even less viable.”
BackgroundLuan, D., Szlam, F., Tanaka, K. A., Barie, P. S., & Varner, J. D. (2010) · Molecular BioSystems · doi:10.1039/b920693k · Cited by 36
Beltrán‐Debón, R., Rodríguez‐Gallego, E., Fernández‐Arroyo, S., Senan, O., Massucci, F. A., Hernández‐Aguilera, A., Sales‐Pardo, M., Guimerà, R., Camps, J., Menéndez, J. A., et al. (2015) · Food & Function · doi:10.1039/c5fo00696a · Cited by 36
Greek, R., & Hansen, L. A. (2013) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2013.06.002 · Cited by 36
Network-Based Identification of Biomarkers Coexpressed with Multiple Pathways
Guo, N. L., & Wan, Y. (2014) · Cancer Informatics · doi:10.4137/cin.s14054 · Cited by 36
Song, Z., Yin, F., Xiang, B., Lan, B., & Cheng, S. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/5194016 · Cited by 36
“In order to understand the pathogenesis of complex diseases a new “multitarget, multidrug” model strategy of drug discovery was presented [7].”
BackgroundSystems Biology Approaches to a Rational Drug Discovery Paradigm
Prathipati, P., & Mizuguchi, K. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150826114524 · Cited by 36
Essential gene identification and drug target prioritization in Leishmania species
Paul, S., Kaur, A., Geete, A., & Sobhia, M. E. (2014) · Molecular BioSystems · doi:10.1039/c3mb70440h · Cited by 35
Nishi, A., Ohbuchi, K., Kushida, H., Matsumoto, T., Lee, K., Kuroki, H., Nabeshima, S., Shimobori, C., Komokata, N., Kanno, H., et al. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0032-1 · Cited by 35
“A theoretical framework to explain how the systematic control of complex biological networks can be achieved via perturbations of long-tail components is being proposed.(52) We conjecture that the contribution of each “tail” component (i.”
Self-citationWeiss, A., Roux-Bourdieu, M. L., Zoetemelk, M., Ramzy, G. M., Rausch, M., Harry, D., Miljkovic‐Licina, M., Falamaki, K., Wehrle‐Haller, B., Meraldi, P., et al. (2019) · Cancers · doi:10.3390/cancers11101612 · Cited by 35
“If properly designed, synergistic drug combinations can (i) enable targeting of deregulated networks from multiple angles [3], thereby challenging the robust and compensatory nature of complex biological systems [4,5], and (ii) allow for effective therapies with reduced toxicity by employing lower single drug doses of…”
BackgroundSingh, R., Prasad, A. A., Kumar, B., Kumari, S., Sahu, R. K., & Hedau, S. T. (2022) · ChemistrySelect · doi:10.1002/slct.202201288 · Cited by 34
DTome: a web-based tool for drug-target interactome construction
Sun, J., Wu, Y., Xu, H., & Zhao, Z. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-s9-s7 · Cited by 34
“Drug efficacy can be affected by the complexity of biological networks, of which targets are only a part; whereas adverse side effects of a drug may be caused by unwanted cross-reactivity with other biologically relevant targets [3,4].”
BackgroundGostner, J. M., Wrulich, O. A., Jenny, M., Fuchs, D., & Ueberall, F. (2012) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-12-18 · Cited by 34
“Many of today’s illnesses are thought to result from environmental and lifestyle changes, which favour an undesirable functioning of biological systems that have evolved over an evolutionary time course [29].”
BackgroundInfluentialYuan, J., Zhu, X., Zhang, X., Yin, H., Feng, E., & Xiu, Z. (2014) · Applied Mathematics and Computation · doi:10.1016/j.amc.2014.01.027 · Cited by 33
Targeted Protein Upregulation of STING for Boosting the Efficacy of Immunotherapy
Cho, W., Won, S., Choi, Y., Yi, S., Park, J. B., Park, J., Kim, C. E., Narayana, C., Kim, J. H., Yim, J., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202300978 · Cited by 34
Yusof, K. M., Makpol, S., Jamal, R. A., Harun, R., Mokhtar, N. M., & Ngah, W. W. (2015) · Molecules · doi:10.3390/molecules200610280 · Cited by 33
“and simultaneous enhancement of therapeutic actions as well as reduction of unwanted actions during treatment [45–47].”
BackgroundNovel targeted therapies for autoimmunity
Clair, E. W. S. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.09.008 · Cited by 33
“Restoring balance to these robust yet dysfunctional systems which in autoimmunity consist of multiple dysregulated cell types on varied genetic backgrounds will likely require higher complexity strategies (67,68).”
BackgroundInvestigation into the mechanism of Eucommia ulmoides Oliv. based on a systems pharmacology approach
Li, Y., Han, C., Wang, J., Xiao, W., Wang, Z., Zhang, J., Yang, Y., Zhang, S., & Ai, C. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.10.067 · Cited by 33
Tools and ingredients for the biocatalytic synthesis of metabolites
Wohlgemuth, R. (2009) · Biotechnology Journal · doi:10.1002/biot.200900002 · Cited by 33
“Central metabolites at branch points play an important role in the regulation of multiple pathways of the cell in metabolic engineering strategies [51–53] and robustness-based approaches to drug design [54].”
BackgroundThe use of molecular markers in the diagnosis and treatment of colorectal cancer
Tejpar, S. (2007) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2007.10.002 · Cited by 33
Learning the drug target‐likeness of a protein
Xu, H., Xu, H., Lin, M., Wang, W., Li, Z., Huang, J., Chen, Y., & Chen, X. (2007) · PROTEOMICS · doi:10.1002/pmic.200700062 · Cited by 33
Zhao, J., Zhang, X., & Zhang, S. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.79 · Cited by 33
Nucleic acid combinations: A new frontier for cancer treatment
Remant Bahadur, K. C., Thapa, B., Valencia‐Serna, J., Aliabadi, H. M., & Uludağ, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.029 · Cited by 32
Targeting the Ubiquitin+Proteasome System in Solid Tumors
Driscoll, J. J., & Woodle, E. S. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.04.002 · Cited by 32
Zhu, P., Aliabadi, H. M., Uludağ, H., & Han, J. (2016) · Scientific Reports · doi:10.1038/srep23078 · Cited by 32
“Various studies have been carried out to estimate the robustness or vulnerability of a system 17–19 .”
Tomasetti, M., Strafella, E., Staffolani, S., Santarelli, L., Neužil, J., & Guerrieri, R. A. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605617 · Cited by 32
“Cancer treatment requires modulation of concrete targets, which can be compromised by the compensatory mechanisms and/or mutations (Stelling et al, 2004; Kitano, 2007).”
BackgroundAnimal Models in an Age of Personalized Medicine
Greek, R., Menache, A., & Rice, M. J. (2011) · Personalized Medicine · doi:10.2217/pme.11.89 · Cited by 32
Subedi, A., Futamura, Y., Nishi, M., Ryo, A., Watanabe, N., & Osada, H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.06.128 · Cited by 31
Optimisation of Cancer Drug Treatments Using Cell Population Dynamics
Billy, F., Clairambault, J., & Fercoq, O. (2012) · Lecture notes on mathematical modelling in the life sciences · doi:10.1007/978-1-4614-4178-6_10 · Cited by 31
“…we have adopted here may indeed be considered as complementary to the one of molecular biologists, pharmacologists and systems theoreticians [77, 78] who seek to control the cell division cycle at the single cell level by targeted drugs that are hoped-for blockers of intracellular pathways…”
BackgroundKuwahara, H., Myers, C. J., & Samoilov, M. S. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000723 · Cited by 29
“Taken together, these results broadly serve to further demonstrate the potential utility of computational and systems biological approaches as we are beginning to understand and control many physiological processes in disease and development at the inter-/ intra-cellular network and circuit levels [113–118], thus enab…”
BackgroundGu, S., Yin, N., Pei, J., & Lai, L. (2013) · Molecular BioSystems · doi:10.1039/c3mb25605g · Cited by 29
A Map of Alzheimer’s Disease–Signaling Pathways: A Hope for Drug Target Discovery
Ogishima, S., Mizuno, S., Kikuchi, M., Miyashita, A., Kuwano, R., Tanaka, H., & Nakaya, J. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.37 · Cited by 29
Effects of hispolon on glioblastoma cell growth
Arcella, A., Oliva, M. A., Sanchez, M., Staffieri, S., Esposito, V., Giangaspero, F., & Cantore, G. (2017) · Environmental Toxicology · doi:10.1002/tox.22419 · Cited by 29
Qu, D., Guo, M., Qin, Y., Wang, L., Zong, B., Chen, Y., & Chen, Y. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1365394 · Cited by 29
“…is now receiving the increasingly concerns, due to the complex physiological mechanism of tumors that monotherapy is incapable of modulating various signaling pathways and thereby failure in highly effective antineoplastic treatment (Hanahan & Weinberg, 2000; Kitano, 2007; Miao & Huang, 2015).”
BackgroundEnsembles of signal transduction models using Pareto Optimal Ensemble Techniques (POETs)
Song, S. O., Chakrabarti, A., & Varner, J. D. (2010) · Biotechnology Journal · doi:10.1002/biot.201000059 · Cited by 29
A Computational Approach to Analyze the Mechanism of Action of the Kinase Inhibitor Bafetinib
Burkard, T. R., Rix, U., Breitwieser, F. P., Superti‐Furga, G., & Colinge, J. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001001 · Cited by 28
“However, biological signaling networks are often highly redundant thus requiring perturbation at several points in order to observe an effect [43].”
BackgroundYe, H., Zheng, C., Xu, X., Wu, M., & Liu, X. (2011) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-011-0853-5 · Cited by 28
Guo, F., Zhang, W., Su, J. Y., Xu, H., & Yang, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00049 · Cited by 28
“Health systems are generally robust against various perturbations but can be fragile when faced with perturbations for which the system has not been optimized (e.g., disease conditions) (Kitano, 2007).”
Background
Metadata
- Authors
- Kitano, H.
- Affiliations
- Sony Computer Science Laboratories (JP)
- Corresponding author
- Kitano, Hiroaki
- ORCID
- Kitano, Hiroaki
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-02-23
- Volume
- 6
- Issue
- 3
- Pages
- 202-210
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1504533062
- Cited by
- 488
- References
- 105
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 9 · 2023: 6 · 2022: 15 · 2021: 8 · 2020: 18 · 2019: 20 · 2018: 16 · 2017: 25 · 2016: 29 · 2015: 37 · 2014: 30 · 2013: 32 · 2012: 47
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- robustness, biological robustness, complex networks, control theory, communication theory, cellular systems, drug efficacy, adverse drug reactions, systems biology
- MeSH terms
- Animals, Communicable Diseases, Pharmaceutical Preparations, Humans, Models, Theoretical, Neoplasms, Technology, Pharmaceutical, Drug Design, Signal Transduction, Cell Proliferation, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.